Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.

Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, Irving WL; HCV Research UK.

Aliment Pharmacol Ther. 2019 May 31. doi: 10.1111/apt.15296. [Epub ahead of print]

PMID:
31149748
2.

Epitope Presentation of Dengue Viral Envelope Glycoprotein Domain III on Hepatitis B Core Protein Virus-Like Particles Produced in Nicotiana benthamiana.

Pang EL, Peyret H, Ramirez A, Loh HS, Lai KS, Fang CM, Rosenberg WM, Lomonossoff GP.

Front Plant Sci. 2019 Apr 16;10:455. doi: 10.3389/fpls.2019.00455. eCollection 2019.

3.

The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis.

Day JW, Rosenberg WM.

Br J Hosp Med (Lond). 2018 Dec 2;79(12):694-699. doi: 10.12968/hmed.2018.79.12.694.

PMID:
30526098
4.

Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.

Agarwal K, Castells L, Müllhaupt B, Rosenberg WMC, McNabb B, Arterburn S, Camus G, McNally J, Stamm LM, Brainard DM, Mani Subramanian G, Mariño Z, Dufour JF, Forns X.

J Hepatol. 2018 Sep;69(3):603-607. doi: 10.1016/j.jhep.2018.05.039. Epub 2018 Jun 8.

PMID:
29886154
5.

A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array.

Peveler WJ, Landis RF, Yazdani M, Day JW, Modi R, Carmalt CJ, Rosenberg WM, Rotello VM.

Adv Mater. 2018 Jul;30(28):e1800634. doi: 10.1002/adma.201800634. Epub 2018 May 24.

PMID:
29797373
6.

Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS).

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Menon U, Rosenberg WM.

BMC Public Health. 2018 Mar 27;18(1):409. doi: 10.1186/s12889-018-5308-x.

7.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B.

Hepatology. 2018 Jun;67(6):2113-2126. doi: 10.1002/hep.29852. Epub 2018 Apr 19.

PMID:
29473975
8.

Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.

Kazaks A, Lu IN, Farinelle S, Ramirez A, Crescente V, Blaha B, Ogonah O, Mukhopadhyay T, de Obanos MP, Krimer A, Akopjana I, Bogans J, Ose V, Kirsteina A, Kazaka T, Stonehouse NJ, Rowlands DJ, Muller CP, Tars K, Rosenberg WM.

BMC Biotechnol. 2017 Nov 10;17(1):79. doi: 10.1186/s12896-017-0396-8.

9.

TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis.

Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK.

Sci Rep. 2017 Jul 17;7(1):5514. doi: 10.1038/s41598-017-05845-5.

10.

Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Jacobs I, Menon U, Rosenberg WM.

BMC Public Health. 2017 Jun 28;17(1):603. doi: 10.1186/s12889-017-4518-y.

11.

T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System.

Huang WC, Easom NJ, Tang XZ, Gill US, Singh H, Robertson F, Chang C, Trowsdale J, Davidson BR, Rosenberg WM, Fusai G, Toubert A, Kennedy PT, Peppa D, Maini MK.

J Immunol. 2017 Feb 1;198(3):1172-1182. doi: 10.4049/jimmunol.1601313. Epub 2016 Dec 28.

12.

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):289-296. doi: 10.1097/MEG.0000000000000789.

PMID:
27906753
13.

Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid.

Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

J Clin Gastroenterol. 2017 Mar;51(3):268-277. doi: 10.1097/MCG.0000000000000581.

PMID:
27380461
14.

Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score.

Swanson S, Ma Y, Scherzer R, Huhn G, French AL, Plankey MW, Grunfeld C, Rosenberg WM, Peters MG, Tien PC.

J Infect Dis. 2016 Apr 1;213(7):1079-86. doi: 10.1093/infdis/jiv567. Epub 2015 Nov 29.

15.

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.

Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, Dusheiko G, Rosenberg WM, Haque T.

Springerplus. 2015 Jul 16;4:357. doi: 10.1186/s40064-015-1137-x. eCollection 2015.

16.

Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis.

Sands CJ, Guha IN, Kyriakides M, Wright M, Beckonert O, Holmes E, Rosenberg WM, Coen M.

Am J Gastroenterol. 2015 Jan;110(1):159-69. doi: 10.1038/ajg.2014.370. Epub 2014 Dec 23.

PMID:
25533003
17.

Equilibrium contrast-enhanced CT imaging to evaluate hepatic fibrosis: initial validation by comparison with histopathologic sampling.

Bandula S, Punwani S, Rosenberg WM, Jalan R, Hall AR, Dhillon A, Moon JC, Taylor SA.

Radiology. 2015 Apr;275(1):136-43. doi: 10.1148/radiol.14141435. Epub 2014 Dec 8.

PMID:
25490188
18.

Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.

Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J.

BMC Gastroenterol. 2014 Aug 7;14:137. doi: 10.1186/1471-230X-14-137.

19.

Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.

Martyn-Simmons CL, Rosenberg WM, Cross R, Wong T, Smith CH, Barker JN.

Br J Dermatol. 2014 Aug;171(2):267-73. doi: 10.1111/bjd.12782. Epub 2014 Jun 18.

PMID:
24942271
20.

Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts.

McLernon DJ, Donnan PT, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Dillon JF.

BMJ Open. 2014 Jun 2;4(6):e004837. doi: 10.1136/bmjopen-2014-004837.

21.

Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.

Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM.

J Viral Hepat. 2014 Jun;21(6):430-8. doi: 10.1111/jvh.12161. Epub 2013 Aug 15.

22.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
23.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
24.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
25.

Management of hepatitis B in pregnant women and infants: a multicentre audit from four London hospitals.

Godbole G, Irish D, Basarab M, Mahungu T, Fox-Lewis A, Thorne C, Jacobs M, Dusheiko G, Rosenberg WM, Suri D, Millar AD, Nastouli E.

BMC Pregnancy Childbirth. 2013 Dec 1;13:222. doi: 10.1186/1471-2393-13-222.

26.

Complexities of HCV management in the new era of direct-acting antiviral agents.

Rosenberg WM, Tanwar S, Trembling P.

QJM. 2014 Jan;107(1):17-9. doi: 10.1093/qjmed/hct181. Epub 2013 Sep 23. Review.

PMID:
24065837
27.

Evaluation of the aspartate aminotransferase/platelet ratio index and enhanced liver fibrosis tests to detect significant fibrosis due to chronic hepatitis C.

Petersen JR, Stevenson HL, Kasturi KS, Naniwadekar A, Parkes J, Cross R, Rosenberg WM, Xiao SY, Snyder N.

J Clin Gastroenterol. 2014 Apr;48(4):370-6. doi: 10.1097/MCG.0b013e3182a87e78.

28.

Treatment decisions and contemporary versus pending treatments for hepatitis C.

Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM.

Nat Rev Gastroenterol Hepatol. 2013 Dec;10(12):713-28. doi: 10.1038/nrgastro.2013.163. Epub 2013 Sep 10. Review.

PMID:
24019151
29.

Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.

Macdonald DC, Singh H, Whelan MA, Escors D, Arce F, Bottoms SE, Barclay WS, Maini M, Collins MK, Rosenberg WM.

Mucosal Immunol. 2014 Jan;7(1):89-100. doi: 10.1038/mi.2013.27. Epub 2013 May 29.

PMID:
23715172
30.

The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis.

Abignano G, Cuomo G, Buch MH, Rosenberg WM, Valentini G, Emery P, Del Galdo F.

Ann Rheum Dis. 2014 Feb;73(2):420-7. doi: 10.1136/annrheumdis-2012-202843. Epub 2013 Mar 19.

PMID:
23511226
31.

Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease.

Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ.

Comp Hepatol. 2012 Dec 28;11(1):5. doi: 10.1186/1476-5926-11-5.

32.

The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).

McLernon DJ, Dillon JF, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Donnan PT.

PLoS One. 2012;7(12):e50965. doi: 10.1371/journal.pone.0050965. Epub 2012 Dec 14.

33.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030.

PMID:
22930399
34.

Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Wasan H; British Society of Gastroenterology.

Gut. 2012 Dec;61(12):1657-69. doi: 10.1136/gutjnl-2011-301748. Epub 2012 Aug 15.

PMID:
22895392
35.

[What is EBM and what is not?].

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS.

Neuere Med Wiss Quellen Stud. 2012;22:13-7. German. No abstract available.

PMID:
22530492
36.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
37.

Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation.

Fowell AJ, Collins JE, Duncombe DR, Pickering JA, Rosenberg WM, Benyon RC.

Biochem Biophys Res Commun. 2011 Apr 8;407(2):277-82. doi: 10.1016/j.bbrc.2011.02.009. Epub 2011 Feb 15.

PMID:
21300026
38.

A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis.

Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V.

Clin Gastroenterol Hepatol. 2011 Feb;9(2):150-5. doi: 10.1016/j.cgh.2010.09.015. Epub 2010 Oct 1.

PMID:
20888433
39.

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus.

Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp ME, Khakoo SI.

Hepatology. 2010 Apr;51(4):1168-75. doi: 10.1002/hep.23477.

40.

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.

He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, Lustigman S.

J Immunol. 2009 Apr 1;182(7):4005-16. doi: 10.4049/jimmunol.0800531.

41.

A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.

Libri NA, Barker SJ, Rosenberg WM, Semper AE.

J Viral Hepat. 2009 May;16(5):315-24. doi: 10.1111/j.1365-2893.2008.01011.x. Epub 2009 Feb 24.

42.

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, Vizzutti F, Pinzani M, Rosenberg WM.

Gastroenterology. 2009 Jan;136(1):160-7. doi: 10.1053/j.gastro.2008.09.013. Epub 2008 Sep 20.

PMID:
18992746
43.

Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities.

Guha IN, Rosenberg WM.

Clin Liver Dis. 2008 Nov;12(4):883-900, x. doi: 10.1016/j.cld.2008.07.010. Review.

PMID:
18984472
44.

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay.

Mayo MJ, Parkes J, Adams-Huet B, Combes B, Mills AS, Markin RS, Rubin R, Wheeler D, Contos M, West AB, Saldana S, Getachew Y, Butsch R, Luketic V, Peters M, Di Bisceglie A, Bass N, Lake J, Boyer T, Martinez E, Boyer J, Garcia-Tsao G, Barnes D, Rosenberg WM.

Hepatology. 2008 Nov;48(5):1549-57. doi: 10.1002/hep.22517.

45.

Renal hepatitis C in the absence of detectable serum or hepatic virus.

Fowell AJ, Sheron N, Rosenberg WM.

Liver Int. 2008 Jul;28(6):889-91. doi: 10.1111/j.1478-3231.2008.01672.x.

PMID:
18647143
46.

A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations.

Cooper K, Bryant J, Picot J, Clegg A, Roderick PR, Rosenberg WM, Patch C.

QJM. 2008 Aug;101(8):631-41. doi: 10.1093/qjmed/hcn070. Epub 2008 Jun 3.

PMID:
18522976
47.

A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.

MacDonald AJ, Libri NA, Lustigman S, Barker SJ, Whelan MA, Semper AE, Rosenberg WM.

Clin Exp Immunol. 2008 May;152(2):265-73. doi: 10.1111/j.1365-2249.2008.03623.x. Epub 2008 Mar 12.

48.

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.

Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2008 Feb;47(2):455-60.

PMID:
18038452
49.

Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells.

MacDonald AJ, Semper AE, Libri NA, Rosenberg WM.

Clin Exp Immunol. 2007 Jun;148(3):494-500. Epub 2007 Mar 15.

50.

Evidence based medicine: what it is and what it isn't. 1996.

Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS.

Clin Orthop Relat Res. 2007 Feb;455:3-5. No abstract available.

PMID:
17340682

Supplemental Content

Loading ...
Support Center